Barinthus Biotherapeutics plc (FRA:2AB)

Market Cap	25.09M -37.1%
Revenue (ttm)	n/a +1,766.5%
Net Income	-64.67M
EPS	-1.60
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.5850
Previous Close	0.5850
Day's Range	0.5850 - 0.5850
52-Week Range	0.5500 - 1.5400
Beta	n/a
RSI	43.06
Earnings Date	Mar 20, 2026

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent high-risk human papillomavirus; VTP-850, an immunothe...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 105
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2AB

Financial Performance

In 2024, Barinthus Biotherapeutics's revenue was $14.97 million, an increase of 1766.46% compared to the previous year's $802,000. Losses were -$61.07 million, -16.73% less than in 2023.

Financial numbers in USD